Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1476-5608

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223 ; volume:25 ; number:2 ; day:26 ; month:8 ; year:2021 ; pages:248-255 ; date:6.2022
Prostate cancer and prostatic diseases ; 25, Heft 2 (26.8.2021), 248-255, 6.2022

Creator: Badrising, Sushil K.
Louhanepessy, Rebecca D.
Noort, Vincent van der
Kieffer, Jacobien
Coenen, Jules L. L. M.
Hamberg, Paul
Beeker, Aart
Wagenaar, Nils
Lam, Marnix
Celik, Filiz
Loosveld, Olaf J. L.
Oostdijk, Ad
Zuetenhorst, Hanneke
Feijter, Jeantine M. de
Dezentjé, Vincent O.
Ras-van Spijk, Suzan
Vegt, Erik
Haanen, John B.
Poll-Franse, Lonneke V. van de
Zwart, Wilbert
Bergman, Andries M.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41391-021-00412-6

URN: urn:nbn:de:101:1-2022082321080882076096

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 26.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Badrising, Sushil K.
Louhanepessy, Rebecca D.
Noort, Vincent van der
Kieffer, Jacobien
Coenen, Jules L. L. M.
Hamberg, Paul
Beeker, Aart
Wagenaar, Nils
Lam, Marnix
Celik, Filiz
Loosveld, Olaf J. L.
Oostdijk, Ad
Zuetenhorst, Hanneke
Feijter, Jeantine M. de
Dezentjé, Vincent O.
Ras-van Spijk, Suzan
Vegt, Erik
Haanen, John B.
Poll-Franse, Lonneke V. van de
Zwart, Wilbert
Bergman, Andries M.
SpringerLink (Online service)

Other Objects (12)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

Related objects

Reset password